103 related articles for article (PubMed ID: 19897232)
1. A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Winer I; Buckanovich RJ
Gynecol Oncol; 2010 Mar; 116(3):578-9. PubMed ID: 19897232
[No Abstract] [Full Text] [Related]
2. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
3. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Liotta M; Rose PG; Escobar PF
Gynecol Oncol; 2009 Nov; 115(2):308-9. PubMed ID: 19740533
[No Abstract] [Full Text] [Related]
4. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
5. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
Kaye SB
J Clin Oncol; 2007 Nov; 25(33):5150-2. PubMed ID: 18024860
[No Abstract] [Full Text] [Related]
6. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report.
Chéreau E; Stefanescu D; Selle F; Rouzier R; Daraï E
Am J Obstet Gynecol; 2009 Jan; 200(1):e15-6. PubMed ID: 19121652
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.
Barrena Medel NI; Herzog TJ; Wright JD; Lewin SN
Anticancer Res; 2010 Nov; 30(11):4767-8. PubMed ID: 21115938
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
11. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
12. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
13. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
14. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
Eskens FA; Sleijfer S
Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
Burkart CM; Grisel JJ; Hom DB
Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
17. [Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
Baba T; Mandai M; Fujii S
Nihon Rinsho; 2004 Oct; 62 Suppl 10():467-70. PubMed ID: 15535289
[No Abstract] [Full Text] [Related]
18. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
19. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.
Numnum TM; Rocconi RP; Whitworth J; Barnes MN
Gynecol Oncol; 2006 Sep; 102(3):425-8. PubMed ID: 16797681
[TBL] [Abstract][Full Text] [Related]
20. Giant mucinous ovarian tumor with low malignant potential with foci of well-differentiated mucinous adenocarcinoma masked by massive obesity. A case report.
Poole SY; Malone JM; Jacques SM; James A
J Reprod Med; 1994 Dec; 39(12):982-4. PubMed ID: 7884758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
